[go: up one dir, main page]

MX2010001307A - Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos. - Google Patents

Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.

Info

Publication number
MX2010001307A
MX2010001307A MX2010001307A MX2010001307A MX2010001307A MX 2010001307 A MX2010001307 A MX 2010001307A MX 2010001307 A MX2010001307 A MX 2010001307A MX 2010001307 A MX2010001307 A MX 2010001307A MX 2010001307 A MX2010001307 A MX 2010001307A
Authority
MX
Mexico
Prior art keywords
rantes
antibodies
methods
modulating
immune
Prior art date
Application number
MX2010001307A
Other languages
English (en)
Inventor
Marie Kosco-Vilbois
Nicolas Fischer
Francois Mach
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of MX2010001307A publication Critical patent/MX2010001307A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con anticuerpos monoclonales completamente humanos, y fragmentos de los mismos, que se unen a la quimiocina Regulada con la activación, Expresada y Secretada por los Linfosictos T Normales (RANTES, CCL5), modulando por lo tanto la interacción entre la RANTES y uno o más de sus receptores, tales como, por ejemplo CCR1, CCR3, CCR4 y CCR5 y/o modulando las actividades biológicas de la RANTES. La invención también se relaciona con el uso de éstos o cualquier anticuerpos anti-RANTES en la prevención o tratamiento de trastornos relacionados con la inmunidad y en la mejora de uno o más de los síntomas asociados con un transtorno relacionado con la inmunidad.
MX2010001307A 2007-08-02 2008-08-04 Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos. MX2010001307A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96327107P 2007-08-02 2007-08-02
PCT/US2008/009382 WO2009054873A2 (en) 2007-08-02 2008-08-04 Anti-rantes antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2010001307A true MX2010001307A (es) 2010-07-30

Family

ID=40580276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001307A MX2010001307A (es) 2007-08-02 2008-08-04 Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.

Country Status (11)

Country Link
US (3) US8012474B2 (es)
EP (1) EP2185719B1 (es)
JP (2) JP5624884B2 (es)
CN (1) CN101802211B (es)
AU (1) AU2008317495B2 (es)
CA (1) CA2695237A1 (es)
DK (1) DK2185719T3 (es)
ES (1) ES2453592T3 (es)
MX (1) MX2010001307A (es)
PT (1) PT2185719E (es)
WO (1) WO2009054873A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2185719B1 (en) * 2007-08-02 2013-11-13 NovImmune SA Anti-rantes antibodies and methods of use thereof
JP2012504953A (ja) 2008-10-07 2012-03-01 ノビミューン エスアー Ｉｌ−１７媒介性トランスフェクション法
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
BR112012004387A2 (pt) 2009-08-28 2015-09-08 Vlst Corp anticorpos anticinas que se l igam a múltiplas quimiocinas cc.
WO2012163848A1 (en) * 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
US20150011431A1 (en) 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
US8891357B2 (en) 2012-08-31 2014-11-18 Cisco Technology, Inc. Switching to a protection path without causing packet reordering
US20150309048A1 (en) * 2012-12-21 2015-10-29 Inserm (Isntitut National De La Sante Et De La Recherche Médicale) Methods and kits for detecting antigen-induced memory cd8+ t cells
WO2014110368A1 (en) * 2013-01-11 2014-07-17 The California Institute For Biomedical Research Bovine fusion antibodies
CN111518199A (zh) 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
IL302725A (en) * 2016-01-13 2023-07-01 Regeneron Pharma Rodents having an engineered heavy chain diversity region
WO2018012889A1 (ko) * 2016-07-13 2018-01-18 (주)아모레퍼시픽 Itac의 억제제를 포함하는 조성물
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
WO1994000569A1 (en) 1992-06-18 1994-01-06 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
AU693097B2 (en) 1993-06-04 1998-06-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for treating kaposi's sarcoma with antisense oligonucleotides
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US7435802B2 (en) * 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
WO1996017935A2 (en) 1994-12-08 1996-06-13 Glaxo Group Limited Rantes peptide and fragments and compositions comprising it for treatment of inflammation
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5834419A (en) 1995-04-19 1998-11-10 The John P. Robarts Institute Chemokine binding protein and methods of use therefor
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
ATE352613T1 (de) 1995-08-29 2007-02-15 Kirin Brewery Chimäres tier und methode zu dessen herstellung
US6025130A (en) 1996-04-04 2000-02-15 Mercator Genetics, Inc. Hereditary hemochromatosis gene
US5840544A (en) 1996-04-17 1998-11-24 Incyte Pharmaceuticals, Inc. DNA encoding rantes homolog from prostate
WO1998006751A1 (en) 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
WO1998013495A1 (en) 1996-09-25 1998-04-02 British Biotech Pharmaceuticals Limited Human rantes mutants incapable of aggregate formation
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
IT1291353B1 (it) 1997-05-12 1999-01-07 San Raffaele Centro Fond Peptidi con attivita' antivirale
EP0906954A1 (en) 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
MXPA00003885A (es) 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
AU1616499A (en) 1997-12-01 1999-06-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chemokine variants and methods of use
EP1040191B1 (en) 1997-12-23 2005-11-02 Fondazione Centro San Raffaele Del Monte Tabor Rantes mutants and therapeutic applications thereof
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1000626A1 (en) 1998-09-18 2000-05-17 Applied Research Systems ARS Holding N.V. Chemokine receptor antagonist and cyclosporin in combined therapy
IT1303736B1 (it) 1998-11-11 2001-02-23 San Raffaele Centro Fond Peptidi derivati da rantes con attivita' anti-hiv.
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6589933B1 (en) 1999-04-02 2003-07-08 Viron Therapeutics, Inc. Myxoma chemokine binding protein
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6420346B1 (en) 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
AU5714801A (en) 2000-04-21 2001-11-07 Chemocentryx Inc Methods and compositions for eliciting an immune response
WO2001089304A1 (en) 2000-05-23 2001-11-29 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
JP4901051B2 (ja) 2000-05-30 2012-03-21 ジョンソン アンド ジョンソン リサーチ プロプライアトリー リミテッド ＲＮＡｉを増強する因子を使用することによって遺伝子抑制を媒介する方法
CA2412436C (en) * 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
MXPA02012434A (es) * 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
AU2001284160A1 (en) 2000-08-19 2002-03-04 Axordia Limited Modulation of stem cell differentiation
WO2002029858A2 (en) 2000-09-29 2002-04-11 Infineon Technologies North America Corp. Deep trench etching method to reduce/eliminate formation of black silicon
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
WO2002043758A2 (en) 2000-12-01 2002-06-06 Schering Corporation Uses of mammalian genes and related reagents
US20020165161A1 (en) 2001-05-04 2002-11-07 Surromed, Inc. Chemokine-binding proteins for treating congestive heart failure
GB0115780D0 (en) 2001-06-27 2001-08-22 Univ Cambridge Tech Therapeutic molecules and uses thereof
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003035106A1 (en) 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
EP1458756B1 (en) 2001-12-17 2009-01-28 Laboratoires Serono SA Chemokine mutants acting as chemokine antagonists
DE60303929T2 (de) 2002-04-04 2006-08-10 Applied Research Systems Ars Holding N.V. Chemokin-muntanten mit verbesserter oraler bioverfügbarkeit
CN1681926A (zh) 2002-09-12 2005-10-12 财团法人化学及血清疗法研究所 人的抗人mcp－1抗体和该抗体的片段
KR100456790B1 (ko) * 2002-09-28 2004-11-10 (주)에스제이바이오메드 미토콘드리아 아데닐레이트 인산화 효소 이소자임3에 특이적인 단클론 항체
US7964194B2 (en) * 2002-11-15 2011-06-21 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
ES2305573T3 (es) 2002-12-23 2008-11-01 Laboratoires Serono Sa Uso de metantes de quimiocinas cc ccl5/rantes contra transtornos del higado.
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
WO2007048186A1 (en) * 2005-10-25 2007-05-03 Baker Medical Research Institute Leukocyte-binding polypeptides and uses thereof
EP2185719B1 (en) * 2007-08-02 2013-11-13 NovImmune SA Anti-rantes antibodies and methods of use thereof

Also Published As

Publication number Publication date
JP2013234204A (ja) 2013-11-21
WO2009054873A3 (en) 2009-12-23
US8012474B2 (en) 2011-09-06
EP2185719B1 (en) 2013-11-13
US8673299B2 (en) 2014-03-18
EP2185719A2 (en) 2010-05-19
WO2009054873A4 (en) 2010-02-11
PT2185719E (pt) 2014-02-20
EP2185719A4 (en) 2012-01-04
US20120201826A1 (en) 2012-08-09
ES2453592T3 (es) 2014-04-08
JP2010535763A (ja) 2010-11-25
US20090148455A1 (en) 2009-06-11
CN101802211B (zh) 2014-10-01
CA2695237A1 (en) 2009-04-30
US20150079099A1 (en) 2015-03-19
WO2009054873A2 (en) 2009-04-30
JP5624884B2 (ja) 2014-11-12
WO2009054873A9 (en) 2009-06-25
DK2185719T3 (en) 2014-02-17
AU2008317495A1 (en) 2009-04-30
CN101802211A (zh) 2010-08-11
AU2008317495B2 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
MX2010001307A (es) Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
MX2009009261A (es) Anticuerpos anti-ip-10 y metodos para su uso.
WO2006109191A3 (en) Human anti-interferon gamma antibodies and methods of use thereof
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
WO2006074428A3 (en) Cxcr4 antagonists for the treatment of medical disorders
MY165273A (en) Anti-cd48 antibodies and uses thereof
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
MX2009008787A (es) Moduladores 2-aminopirimidina del receptor de histamina h4.
PH12013500355A1 (en) Engineered anti-tslp antibody
MY156816A (en) High affinity human antibodies to human angiopoietin-2
MY146664A (en) Antibodies against human il-22 and uses therefor
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
TW200736274A (en) Immunoglobulins
MX2007004936A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1.
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
TW200736275A (en) Methods and compositions for treating allergic diseases
PL1830881T3 (pl) Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie
MX2010008060A (es) Anticuerpos humanizados especificos para el factor von willerbrand.
MY184241A (en) Human antibodies to gfr?3 and methods of use thereof
MY158927A (en) Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
TW200621244A (en) Modulators of muscarinic receptors
WO2009139853A3 (en) Human monoclonal antibodies against human chemokine receptor ccr7
MY149448A (en) Interleukin-21 receptor binding proteins
MX2010001187A (es) Moduladores del receptor ccr9 y metodos para su uso.
MX2007006382A (es) Moduladores de receptores muscarinicos.

Legal Events

Date Code Title Description
FG Grant or registration